Antimicrobial potential of compounds from the MMV pandemic response box and COVID box against carbapenem-resistant Acinetobacter baumannii.

Melo ALF, de Cássia Cerqueira Melo R, Martins AA, Sturaro MC, Arantes JP, Vicente JCP, Laleu B, Besson D, Rossato L, de Almeida de Souza GH, Simionatto S

Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]8 Oct 2025

PMID41060575PMCIDPMC12660538DOI10.1007/s42770-025-01641-wPepBankPUB-41060575

Source link PubMedAsk about this study

Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

1 result from studies that gave the peptide. No result from this study comes from people.

01LabIn vitro (cells)Activity measurement
In carbapenem-resistant A. baumannii laboratory screening, brilacidin was among compounds with notable antimicrobial activity.
In plain wordsIn lab tests, brilacidin showed antimicrobial activity against carbapenem-resistant Acinetobacter baumannii.
Peptide
Brilacidin
Outcome
Not applicableAntimicrobial activity
Study
Acinetobacter baumanniin: not reported in source
carbapenem-resistant Acinetobacter baumannii
Outcome group
Infection and antimicrobial activity · Infection
Studied dose
Dose not stated
Source sentences
Summary
Among the tested compounds, 10 demonstrated notable antimicrobial activity, including doxycycline, atazanavir, alexidine, eravacycline, erythromycin, gepotidacin, trimetrexate, MMV1634402 (brilacidin), MMV1580854 and MMV1578564.
Report a problemFND-4106057501

Studies that did not test the peptide alone1

In this study, Brilacidin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Brilacidin.

02LabNot a test of Brilacidin aloneIn vitro (cells)Activity measurement
In carbapenem-resistant A. baumannii laboratory tests, brilacidin plus meropenem showed synergy with FICI = 0.37.
In plain wordsIn lab tests, brilacidin plus meropenem showed synergy against carbapenem-resistant Acinetobacter baumannii.
Peptide
Brilacidin
Outcome
Not applicableMeropenem combination synergy
Study
Acinetobacter baumanniin: not reported in source
carbapenem-resistant Acinetobacter baumannii
Outcome group
Infection and antimicrobial activity · Infection
Measurements
FICI
0.37
brilacidin plus meropenem
Source sentences
Summary
Synergy testing revealed a strong synergistic effect (FICI = 0.37) between brilacidin and meropenem, enhancing antibacterial efficacy.
In this study, Brilacidin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Brilacidin.
Report a problemFND-4106057502

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
27 Oct 2026, 18:20 UTC
Study results updated
Version 1
27 Oct 2026, 16:32 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.